Ocugen On Friday Announced Its COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shared Phase 3 Results; Co. Reported 'Efficacy analysis demonstrates COVAXIN to be 93.4% protective against severe symptomatic COVID-19 and 65.2% protection against'